Locally advanced breast cancer: Is PET useful for monitoring primary chemotherapy?

Journal of Nuclear Medicine

Volumn 44, Issue 11, 2003, Pages 1815-1817

  Biersack, Hans J ^a   Palmedo, Holger ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TECHNETIUM 99M; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

BIOLOGICAL MONITORING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCTION; TUMOR CELL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; SCINTISCANNING;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0642345824     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (18)

1. Mankoff DA, Dunnwald LK, Gralow JR, et al Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814.
2. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer, findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493
3. Booser DJ, Hortobagyi GN Treatment of locally advanced breast cancer. Semin Oncol. 1992;19:278-285.
4. Machiavelli M, Romero A, Pérez K, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-131.
5. Chollet P, Chamer S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997;3:862-866.
6. Vinnicombe SJ, MacVicar AD, Guy RL, et al Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology, 1996;198:333-340.
7. Mankoff DA, Dunnwald LK, Gralow JR. et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509
8. Palmedo H. What can we expect from MDR breast cancer imaging with sestamibi? J Nucl Med. 2002;43:526-529
9. Sagar SM, Klassen GA, Barclay KD, Aldrich JE. Tumor blood flow: measurement and manipulation for therapeutic gain. Cancer Treat Rev 1993;19:299-349.
10. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography, a rapid and noninvasive dynamic method. Cancer Res. 1992;52:1592-1597.
11. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer. 1999;85:2410-2423
12. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139-168.
13. Wahl R, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111
14. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol. 2000;18:1689-1695.
15. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol. 2000;18:1676-1688.
16. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2002;27:683-687.
17. Bender H, Bangard M, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87-91.
18. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56.